(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release →
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria